Cargando…
eIg-based bispecific T-cell engagers targeting EGFR: Format matters
Bispecific antibodies are molecules with versatile modes of action and applications for therapy. They are commonly developed as T-cell engagers (TCE), which simultaneously target an antigen expressed by tumor cells and CD3 expressed by T-cells, thereby inducing T-cell-mediated target cell killing. T...
Autores principales: | Kühl, Lennart, Schäfer, Annelie K., Kraft, Sebastian, Aschmoneit, Nadine, Kontermann, Roland E., Seifert, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988351/ https://www.ncbi.nlm.nih.gov/pubmed/36864566 http://dx.doi.org/10.1080/19420862.2023.2183540 |
Ejemplares similares
-
The eIg technology to generate Ig-like bispecific antibodies
por: Kühl, Lennart, et al.
Publicado: (2022) -
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021) -
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
por: Aschmoneit, Nadine, et al.
Publicado: (2021) -
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)
por: Aschmoneit, Nadine, et al.
Publicado: (2022) -
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)